CAH

Business Context and Reporting Period

Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 2002 (First Quarter of Fiscal 2003)
Business Overview: The Company operates in four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.

Key Financial Metrics

Margin Analysis: Total Company gross margin as a percentage of operating revenue decreased to 8.82% from 9.27% in the prior year, primarily due to a higher mix of lower-margin pharmaceutical distribution revenue.

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 16% year-over-year, driven by higher sales volume, pharmaceutical price increases (approx. 5%), new products, and acquisitions.
• Earnings Growth: Net earnings increased significantly ($288.3M vs $176.3M). The prior year included a one-time cumulative effect of a change in accounting ($70.1M) which boosted prior year earnings; excluding this, organic growth remains strong.
• Cash Flow: Net cash used in operating activities was $14.1 million, a significant improvement from $480.7 million used in the prior year. This was driven by a decrease in inventory levels ($110.8M) offset by increases in trade receivables ($264.9M) and decreases in accounts payable ($204.7M).
• Share Repurchases: The Company repurchased $392.7 million of Common Shares during the quarter, significantly impacting cash balances and shareholders' equity.

Guidance, Outlook, Risks, and Unusual Items

Special Charges and Unusual Items

• Total Special Charges: $18.7 million (net of tax: $15.6 million reduction in earnings).
• Components:
  • Merger-Related Costs: $11.4 million (Bindley, BBMC, Allegiance, Scherer integrations).
  • Manufacturing Facility Closures: $10.2 million charge in the Medical-Surgical segment (asset impairments, exit costs, severance).
  • Litigation Settlements: $2.9 million income from antitrust claims against vitamin manufacturers.
• Future Costs: Management estimates approximately $76.8 million in additional merger and restructuring costs to be incurred in fiscal 2003 and 2004.

Pending Transaction (Syncor)

The Company announced a pending acquisition of Syncor International Corporation (approx. $950 million value). However, on November 6, 2002, Syncor announced an investigation into improper payments by foreign subsidiaries, postponing the shareholder vote. The Company is continuing due diligence; completion of the transaction is not assured.

Risks and Contingencies

• Latex Litigation: 368 pending lawsuits regarding natural rubber latex sensitization. Potential liability estimated between $0 and $20 million net of insurance, though exact quantification is not possible.
• Kmart Bankruptcy: Kmart represents approx. 5% of operating revenue. The Company has limited credit exposure due to consignment arrangements and does not anticipate a material impact.
• Market Risk: No material change in market risks from the previous 10-K.

Investor Verification Checklist

• Syncor Acquisition Status: Verify the outcome of Syncor's internal investigation and whether the merger agreement conditions will be satisfied.
• Special Charge Run-Rate: Confirm the timing and magnitude of the estimated $76.8 million in future restructuring costs.
• Margin Pressure: Monitor the mix of revenue between low-margin distribution and high-margin services to assess future gross margin trends.
• Liquidity Management: Review the impact of continued share repurchases ($500M authorization active) on working capital and cash reserves.
• Legal Exposure: Track developments in the latex litigation and vitamin antitrust settlements for potential financial impact.